We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
B-North is a financial technology bank combining cloud-native technology with face-to-face relationship banking to disrupt the £150 billion UK Small and Medium Enterprise (SME) lending market. It argues that it delivers cash to SMEs faster than the competition by combining its lending origination platform with a locally delivered servicing and relationship model overseen by experienced bankers. B-North asserts that it is engaging in a positive dialogue with several potential investors with a committed investment now standing at £18.6 million since June 2020. The company has also raised a seed capital of over £6.8 million that includes a six-figure investment from the Greater Manchester Combined Authority to establish its core team and create both the lending and deposit-taking platforms. The company will use the investment to provide a cash runway to the end of Q2 2021 as the team finalises its Series A round and secures its banking license.
days to go: Expired investment: £883,835
B-North is creating an SME business bank that will deliver fast decisions with loans being given in two weeks. Its model is formed around strong relationships with both brokers and customers. B-North is in a positive conversation with the British Business Bank for Tier 2 debt, and its FinTech enabled lending platform is excellent. The funds will be used to expand the team and develop the platform. The company also aims at assembling a highly-experienced and ambitious management team supported by a heavyweight board.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £2,815,350
HealthBox Software is a technology company building products for the post-COVID healthcare landscape. Its first product, ClearPass, was met with success. The tool asks an employee a series of screening questions related to COVID-19, including evidence of fever, fatigue, and dry cough, etc. ClearPass has over 400,000 end-users including companies like Johnson Controls, Remy Cointreau and the San Diego School District. HealthBox aims to be a significant contender in the global digital health market that is expected to be worth $600 billion by 2026. The company is on the verge of launching another innovative product, MyHealthBox. It is a consumer-facing digital health app that will allow users to store their medical records, easily accessible 24/7. HealthBox asserts that the app will have an array of features, including AI health assessment services, dietary advice and data-powered lifestyle guidance. The company will use 47% of the investment towards technology and development costs, and 53% towards sales and marketing.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £144,265
DAG Global is the premier digital assets merchant bank seeking to re-establish the connection between client and bank to promote dynamic growth. DAG is well placed to provide banking services to an already growing and sizable market like the digital, fintech, and SME. Currently, DAG Global is applying to the PRA to receive a full UK banking license so that they can clear directly with the Bank of England. This will also enable it to lend to clients and take deposits. Its existing unregulated business lines include OTC, digital assets lending, and direct investment platform.
days to go: Expired investment: £2,076,840
Belluscura aims at attending millions of people worldwide who are suffering from chronic lung diseases by providing them with the X-PLOR, portable, a lightweight, oxygen delivery device. It has developed it mainly to improve both the mobility and the life quality of the patients suffering from Chronic Obstructive Pulmonary Disease globally. It also has an exclusive license to a patented portable oxygen concentrator, the X-PLOR, that supplies 96% pure oxygen to patients 24/7. It's X-PLOR weights only 1.4kg and is 33% lighter, and provides 37% more oxygen per kg than its leading opponents. As smoke, pollution, and lives increase, the oxygen market will continue to grow from £1.1bn to £1.9bn by 2024. So, according to its market research, a 3% market share within 3 years could generate £46m in sales. With the funds raised, it is planning to extend its proprietary oxygen platform technology into other multi £bn markets such as wound care and sleep. Furthermore, it has filed patents on a next-generation portable artificial lung.
days to go: Expired investment: £543,670
Future Planet is an investor-led, co-investment platform giving entrepreneurs a reliable and profitable platform to solve the world's greatest challenges like health, climate change, education, sustainable growth & security. Until now, venture capital has been accessible mostly to insiders, institutions and some high-net-worth individuals (HNWI's) but Future Planet is democratising this stage of investment. It allows world-renowned institutions such as Tel Aviv University, Stanford University and Cambridge University and more to have a stake in Future Planet and access the growth generated by its participating companies in Silicon Valley, the Eastern Seaboard, Europe, Israel and Asia. Since its founding, the company has brought $100 million from some of the world's largest investors, raised and invested its first fund and invested with important companies and renowned managers. The company plans to use the investment and momentum to launch the second Future Planet Fund in 2021 and continue its growth with a target of $500 million in Assets Under Management (AUM) by 2025.
days to go: Expired investment: £1,553,118
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph